Wikisage, the free encyclopedia of the second generation, is digital heritage

Difference between revisions of "Belzutifan"

From Wikisage
Jump to navigation Jump to search
Line 7: Line 7:
 
==ATC==
 
==ATC==
 
<gallery>File:Belzutifan.png</gallery>
 
<gallery>File:Belzutifan.png</gallery>
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms/ref>
+
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref>
 +
 
 
{{wikidata|Q27456641}}
 
{{wikidata|Q27456641}}

Revision as of 23:24, 13 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

Q27456641 op Wikidata  Interwiki via Wikidata